AIP
PRAX icon

Arrowpoint Investment Partners’s Praxis Precision Medicines PRAX Stock Holding History

Arrowpoint Investment Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824K Sell
2,461
-1,394
-36% -$441K 0.18% 59
2026
Q1 		$1.24M Buy
3,855
+1,773
+85% +$548K 1.1% 21
2025
Q4 		$614K Buy
+2,082
New +$388K 0.09% 63

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Arrowpoint Investment Partners's PRAX Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its Praxis Precision Medicines (PRAX) stake by 36% in Q2 2026, selling an estimated $441K and leaving 2,461 shares worth $824K. The position accounts for 0.18% of the portfolio, ranked #59.

Arrowpoint Investment Partners first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.24M in Q1 2026. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Arrowpoint Investment Partners held 2,461 shares of Praxis Precision Medicines worth $824K as of Q2 2026.
  • Arrowpoint Investment Partners sold 1,394 Praxis Precision Medicines shares in Q2 2026, an estimated $441K.
  • Praxis Precision Medicines made up 0.18% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #59 holding.
  • Arrowpoint Investment Partners first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • Arrowpoint Investment Partners's Praxis Precision Medicines position peaked at $1.24M in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.